Welcome to our dedicated page for Leap Therapeutic SEC filings (Ticker: LPTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings archive for Leap Therapeutics, Inc. under the historical ticker LPTX provides official documentation of the company’s evolution into Cypherpunk Technologies Inc. and its dual focus on oncology therapeutics and a Zcash-centered digital asset treasury strategy. Forms 8-K detail key events such as the October 2025 private placement led by Winklevoss Capital, adoption of the digital asset treasury strategy, and subsequent name change to Cypherpunk Technologies Inc., along with the planned shift to trading under the symbol CYPH on the Nasdaq Capital Market.
Regulatory reports describe capital markets transactions, including the issuance of common stock, pre-funded warrants, and common warrants, registration rights agreements, and a controlled equity offering sales agreement that allows at-the-market issuances of common stock. Other filings outline Nasdaq bid price deficiency notices, the grant of an additional compliance period, and the company’s consideration of a reverse stock split to address listing standards.
Filings also cover corporate governance and compensation, such as consulting and employment agreements with new digital asset–focused leadership, equity incentive awards in the form of restricted stock units, and board expansion and nomination rights for the lead investor. The definitive proxy statement for a special meeting explains proposals to increase authorized shares, authorize a reverse stock split range, adopt a new equity incentive plan, and approve additional share issuance under the private placement warrants.
For those analyzing the oncology side of the business, 8-Ks and related exhibits reference the wind-down of the DeFianCe clinical trial, reductions in research and development activities, and the exploration of strategic alternatives for sirexatamab and FL-501. On Stock Titan, these filings are paired with AI-powered summaries that help interpret complex agreements, capital structure changes, and disclosure language, while real-time updates from EDGAR ensure that new 10-K, 10-Q, 8-K, and proxy materials for the issuer formerly known as Leap Therapeutics are quickly accessible.
Schilsky Richard reported acquisition or exercise transactions in this Form 4 filing.
Cypherpunk Technologies director Richard Schilsky increased his equity stake through RSU settlements, not open-market buying. On March 13, 2026, 74,700 Restricted Stock Units granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 were each settled 1-for-1 into common shares for no cash consideration. Both RSU awards had vested at issuance. Following these conversions, Schilsky directly holds 168,750 shares of Cypherpunk Technologies common stock as reported in the filing.
Cypherpunk Technologies director Joseph Loscalzo acquired 168,750 common shares through RSU settlements. On March 13, 2026, 74,700 RSUs granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 were each settled on a 1-for-1 basis for common stock at no cash exercise price.
Both RSU grants had vested at issuance under the company’s 2022 and 2025 Equity Incentive Plans, and this Form 4 shows a compensation-related derivative exercise rather than any open-market buying or selling. Following these transactions, Loscalzo directly holds 168,750 shares of Cypherpunk common stock with no remaining RSU position reported.
Cypherpunk Technologies Inc. director James H. Cavanaugh acquired shares through the settlement of previously granted restricted stock units (RSUs). On March 13, 2026, 74,700 November 2025 RSUs and 94,050 December 2025 RSUs each settled on a 1-for-1 basis into common stock, totaling 168,750 shares.
These RSUs were granted for no cash consideration under the company’s 2022 and 2025 equity incentive plans and had vested at issuance. After these non‑cash, compensation-related exercises/conversions, Cavanaugh directly owned 168,963 shares of Cypherpunk common stock, with no open‑market buying or selling reported in this filing.
Cypherpunk Technologies Inc. reports a transformed business model that combines a privacy-focused digital asset strategy with ongoing cancer drug development. The company changed its name from Leap Therapeutics to reflect a new emphasis on Zcash, a privacy-preserving blockchain network and digital asset.
Cypherpunk is accumulating ZEC as a digital asset treasury; as of March 11, 2026 it held 294,743.10 ZEC at an average purchase price of $335.89, about 1.76% of circulating supply, with a goal of reaching at least 5% over time. The firm also invested $5 million in Zcash Open Development Lab to support the core Zcash wallet and protocol development.
Through its Leap Therapeutics subsidiary, the company continues to develop sirexatamab (DKN-01) for colorectal cancer and other indications, with Phase 2 data showing higher response rates and longer progression-free survival in biomarker-selected patients. A second program, FL-501, targets GDF-15 for cachexia and related conditions. Extensive patent portfolios and licensing agreements with Eli Lilly and Adimab underpin its biotechnology assets.
Cypherpunk Technologies reported a sharp turnaround for 2025, posting net income of $4.8 million after a net loss of $67.8 million in 2024. Results were driven mainly by a $50.4 million unrealized gain on the fair value of its Zcash (ZEC) digital asset treasury.
Operating expenses fell as research and development dropped to $25.7 million and general and administrative to $10.9 million, helped by reduced clinical and payroll costs following completion of the sirexatamab Phase 2 program and headcount reductions. At year-end 2025, cash and cash equivalents were $14.0 million, while ZEC treasury holdings recorded as a digital asset receivable totaled $147.4 million, reflecting the company’s new privacy-technology and Zcash-focused strategy funded by a prior $58.88 million private placement.
Cypherpunk Technologies Inc. received a notice from Nasdaq that its common stock has closed below the required $1.00 per share minimum bid price for 30 consecutive business days, putting it out of compliance with Nasdaq Listing Rule 5550(a)(2).
The notice is a deficiency warning, not an immediate delisting, and the stock continues to trade on the Nasdaq Capital Market. The company has 180 days, until August 31, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for 10 straight business days, and may qualify for an additional 180-day period if other listing standards are met.
Cypherpunk plans to monitor its share price and may pursue options such as a reverse stock split to restore compliance, but there is no assurance it will succeed within the initial or any additional compliance period.
Cypherpunk Technologies Inc. (CYPH) is the subject of an amended Schedule 13G filing by Gilead Sciences, Inc. covering its holdings of Cypherpunk common stock, par value $0.001 per share, CUSIP 52187K200.
Gilead now reports beneficial ownership of 0 shares of Cypherpunk common stock, representing 0% of the class, with no sole or shared voting or dispositive power. The filing states that Gilead's ownership is now "5 percent or less" of the class.
Gilead certifies that any securities referenced were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Cypherpunk, nor in connection with any transaction intended to have that effect.
Cypherpunk Technologies Inc. reported that it has expanded its cryptocurrency treasury by purchasing an additional $18 million of Zcash (ZEC) on November 18, 2025. This new purchase totals 29,869.29 ZEC at an average price of $602.63 per ZEC. The company previously acquired 203,775.27 ZEC for approximately $50 million at an average price of $245.37 per ZEC. After the latest transaction, Cypherpunk now holds 233,644.56 ZEC at an overall average cost of $291.04 per ZEC, representing 1.43% ownership of the Zcash network.
Cypherpunk Technologies Inc. (CYPH) reported an insider equity grant on a Form 4. On 11/11/2025, Director and officer Douglas E. Onsi received 2,087,287 restricted stock units (RSUs) under the company’s 2016 Equity Incentive Plan for $0 consideration.
The RSUs vest as follows: 12/36th on October 8, 2026 and 1/36th on the 8th day of each month thereafter, subject to continued service. Vested RSUs will be settled in common stock at the earliest of: the first payroll period after the end of the reporting person’s employment or service, the first payroll period on or after the 8th day of June following any applicable Vesting Date, or the first payroll period on or after the 8th day of December following any applicable Vesting Date.
Cypherpunk Technologies Inc. (CYPH) reported a director equity grant. On November 11, 2025, the director received 74,700 restricted stock units (RSUs) under the Company’s 2022 Equity Incentive Plan for no consideration, each RSU deliverable into one share of common stock.
The RSUs vested at issuance on the grant date. Settlement into common shares will occur as soon as practicable after the earlier of the fifth business day following the director’s service ending or the first annual meeting of stockholders following the grant date.